FluMist nasal spray vaccine approved for self-administration or caregiver use for 2025-26 season, first flu vaccine at home, FDA September 20, 2024.
Trials demonstrate 85% efficacy neutralizing influenza strains for high-risk groups, promising injection-free immunity and broader pediatric adoption.
University of Hong Kong’s intranasal H5N1 vaccine protects against clade 2.3.4.4b in small animal models, April 8, 2025, Nature Communications.
ACIP recommends FluMist for 2-49 years, trivalent for 2025-26 targeting H1N1, H3N2, B/Victoria, avoiding quadrivalent B/Yamagata.
Self-administration option reduces clinic burdens 40%, enhancing vaccination rates amid 610,000-1.3 million hospitalizations 2024-25 season.
Live attenuated influenza vaccine (LAIV) starts mucosal immunity, 60% effective against hospitalization, 50% outpatient CDC interim estimates.
This trial’s quiet advancement unveils new era where nasal’s vast spray bridges injection voids, transforming immunity with enduring harmony.
